Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04684108
What this trial is testing

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Who this might be right for
Relapsed or Refractory Multiple MyelomaHematological Malignancy
Hangzhou Sumgen Biotech Co., Ltd. 61
Early research (Phase 1)WithdrawnNCT04355039
What this trial is testing

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin
Not applicableNot Yet RecruitingNCT06594211
What this trial is testing

Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma

Who this might be right for
Multiple Myeloma
RenJi Hospital 18
Not applicableStudy completedNCT00521430
What this trial is testing

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Asan Medical Center 30
Not applicableStudy completedNCT02976493
What this trial is testing

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 500
Testing effectiveness (Phase 2)Looking for participantsNCT07018050
What this trial is testing

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 160
Early research (Phase 1)Ended earlyNCT00687674
What this trial is testing

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 13
Testing effectiveness (Phase 2)UnknownNCT06223646
What this trial is testing

KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. 29
Large-scale testing (Phase 3)Study completedNCT01564537
What this trial is testing

Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Takeda 722
Testing effectiveness (Phase 2)Ended earlyNCT05191472
What this trial is testing

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Alfred Chung, MD 3
Early research (Phase 1)Study completedNCT01241292
What this trial is testing

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 7
Early research (Phase 1)Study completedNCT00689507
What this trial is testing

Safety Study of LY2127399 in Combination With Bortezomib

Who this might be right for
Multiple Myeloma
Applied Molecular Evolution 48
Early research (Phase 1)Not Yet RecruitingNCT07726160
What this trial is testing

KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapse and/or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 30
Early research (Phase 1)Study completedNCT02920697
What this trial is testing

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Chronic Lymphocytic Leukaemia (CLL)B-Cell Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)
Institut de Recherches Internationales Servier 65
Early research (Phase 1)Ended earlyNCT04895410
What this trial is testing

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 8
Early research (Phase 1)Study completedNCT04000282
What this trial is testing

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Sanofi 37
Large-scale testing (Phase 3)Study completedNCT01712789
What this trial is testing

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 682
Early research (Phase 1)Study completedNCT00884546
What this trial is testing

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Who this might be right for
Advanced Cancer, Various, NOS
Bristol-Myers Squibb 27
Testing effectiveness (Phase 2)Ended earlyNCT03512353
What this trial is testing

Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 7
Testing effectiveness (Phase 2)Ended earlyNCT00861965
What this trial is testing

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Who this might be right for
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Mirror Biologics, Inc. 2
Next Page